Given the fact that the predictive and prognostic role of p53 alterations in GC is still not clear, the aim of our study was to determine the impact of p53 expression in a comprehensive analysis of overall 694 carcinomas of the stomach and gastroesophageal junction including pretherapeutic biopsies of patients before preoperative chemotherapy (CTx). This evidence concerns the gene TP53 and gastric cancer.